LILRB4 and acute myeloid leukemia: A study on the identification and development of a LILRB4-specific human monoclonal antibody, h128-3, demonstrated its potent activity in blocking AML development in monocytes in a variety of mouse models, including patient-derived xenograft mice and homozygous immunocompetent AML mice.